They must be one of the following:
1/ paid by MMs/IIs to sow doubt (boooo)
2/ have an open short on SNG (nice timing what!)
3/ have sold elsewhere and now trying to scrape in as low as poss. (shame on you)
Seems every day now something new with mini positive steps to the big RNS (all in good time of course)
Have a good weekend all, try to it make sure you have an empty bladder 06.55 am Monday because you never know when lift off will be.
@SANG - I notice you're a big supporter of 4D - unlike SNG is there ANY proof of concept (PoC) yet over in that company???? - if there was then there wouldn't be a massive and gentle erosion of the share price down to around GBP£60m. Its easy for companies to pretend to pursue new innovative platform technologies and tools (remember Theranos?).... I'm very skeptical of this 4-D approach unless you can give me any real data on efficacy??? Maybe you are looking to come on board, no trouble buy in buddy below 250p its as cheap as chips for the near term cashflow potential unlike 4D.
Also anuj. There is a very large amount of publicly available information that indicates a successful outcome right now that the small share buyer can point to in his defences rather than any dirty inside info driving his decision to buy stock...
Yes it can it should be at £2.50 min right now = I think the large excess of weekly smoke signals from within chief RM's Tee-pee are now indicating his tent is just about to catch fire and then we will all see the large size of his charcoal BBQ and uncontrolled flames of excitement!
I'm not surprised everyone is buying more into this stock right now....
I think the large excess of weekly smoke signals from within chief RM's Tee-pee are now indicating his tent is just about to catch fire and then we will all see the large size of his charcoal BBQ and uncontrolled flames of excitement!
I'm not surprised everyone is buying into this stock right now....
Hi Japanone - I would hedge your bets, sell 50% at your target exit price say £4/shr. Leave the rest to grow; sell 4-5 months later then pay-off the mortgage and then buy a small pacific island hideaway with the residual cash - makes more sense of use of your capital and investment seriously think hard on this...but you will be informed when the P3 news comes out your gut feel will guide you to the best wealth outcome Im sure not me!
Correct. Sng share purchases now are advantaged and proven as being under fair value "Beyond Reasonable Doubt".
"Jeffrey Archer demonstrated his excellent grasp of share dealing in his 1987 play, Beyond Reasonable Doubt, where the main character, Sir David Metcalfe, makes investments thanks to "advice from an old friend" about a takeover bid.
Lord Archer can hardly have guessed that, seven years after his play packed the Queen's Theatre, in the West End, he would find himself embroiled in a share dealing affair."
Correct. This does not preclude results coming at Any Time. In Brookes husbands. Defense, if this were challenged in any way as insider trading, I would argue that there is such a massive amount of public domain knowledge out of the bag now indicating a positive clinical trial outcome and launch 95% probable that it became irresistible to buy the stock as an outside investor. The company itself has leaked a SOFT RNS in phase 3 outcome via in its own strategic actions and news releases. SO this investor will not be going to jail and has legitimate grounds to trade
That's a bit cheeky, knowing the C suite have seen the outcome! She must be party to news planning and see all the commerial infrastructure being built. More smoke, they think they can get away with it as its such a small investment
I tend to agree Justdeezerts. Bags of future growth but 2021 was the bum year since 2020 was bigger than normal due to covid and over stocking fear from end customers then getting unwound in 21. Nothing we didn't already know in my opinion. But moreover, JS has been unusually bullish in his language ALL over the RNS which speaks volumes to me as he doesn't often give away future outlook specifics. Clear there is lots of value uplift here for a medium term investors. His quote: "have already created substantial progress towards market expectations for 2022." He's saying that the end year 22 revenue forecast is largely de-risked since customers have committed to reformulate and can't really back out. Eg great growth as new cleaning customers come online 100% etc and new applications they are working on to diversify. I'm still very relaxed about holding here for bigger returns as the downside risk in this stock is low and it has intent to diversify strongly in coming years.
This is potentially big for us and as key support for future pandemic planning/stockpiling.... any one know a good agnostic product that can be toll out-license manufactured at scale with a very very fat royalty agreement to the originator?
So its a bit of a sanity check on patient understanding of their hospital release questionnaires for either the long covid part of the trial observation or in the latter part of the recovery process at home?
I know we have no RNS clinical data yet but surely all of this give away advertising jobs stuff in the 'public domain' cannot be totally extraneous to our Phase 3 expectations??? RM & Co information releases sort of inside information / insight on the quality of the data or am I barking mad? I did take the top up like many other in last few days but thinking more may be needed tomorrow!
I think that this pesky "virus" and all the "mutants" yet to be born from within our massive global human reservoir (not to mention cross infection and circulation risks to/from pets / farm animals / birds etc) has more "stealth, speed and agility" than man's combined efforts of pharma innovators, healthcare systems and Government in total, so your £1Bn value could easily be very materially understated...just watch and learn my friend over 2022-2025, the virus will be having more fun than you anticipate.
Dear MumboJumbo (apt name!) - you have completely missed the point with a very short sighted comment.... SNG001 is far bigger than any one COVID mutation or another, don't you get it yet? The other broader respiratory infectious disease therapy segments offer a massive market opportunity that dwarfs the current SP. Good luck buddy with your share buying plan! PS I've been in touch with 2 Big pharma colleagues in recent weeks and they tell me there is "watch-list" interest on P3 results, so that may help you in your little investment decision. :-)